Granocyte

Granocyte is a prescription medication that contains the active ingredient lenograstim, a granulocyte colony‑stimulating factor (G‑CSF) analog. It is supplied in an injectable form for intravenous or subcutaneous administration. Granocyte is marketed in the European Union and is used as a hematopoietic growth factor to support neutrophil production in patients undergoing myelosuppressive therapy. The product is prescribed by oncologists or hematologists and is stored under temperature conditions to maintain stability.

Granocyte is indicated for clinical situations where neutrophil recovery is needed after myelosuppressive treatments.

- To reduce the duration of neutropenia following chemotherapy in cancer patients. - To support neutrophil counts after autologous or allogeneic stem cell transplantation. - To mobilize peripheral blood progenitor cells for collection prior to transplantation. - To treat severe chronic neutropenia in patients with congenital or acquired disorders. - To facilitate faster hematologic recovery in patients receiving high‑dose radiation therapy.

The safety profile of lenograstim includes a range of observed adverse events that vary in frequency and severity.

Common: - Bone pain, especially in the lower back or hips. - Mild fever or chills. - Injection site reactions such as redness, swelling, or itching. - Fatigue or general weakness. - Elevated liver enzymes.

Serious: - Splenic rupture, a rare but potentially life‑threatening condition. - Acute respiratory distress syndrome (ARDS) or severe pulmonary edema. - Allergic reactions including anaphylaxis, characterized by rash, swelling, and difficulty breathing. - Thrombotic events such as deep‑vein thrombosis. - Severe hypotension or shock related to hypersensitivity.

When prescribing Granocyte, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

- Assess baseline neutrophil counts and overall bone marrow function before initiating therapy. - Use caution in patients with a history of splenic enlargement or trauma. - Monitor for signs of hypersensitivity during and after each injection. - Adjust dose or discontinue if persistent fever or unexplained infections develop. - Avoid use in patients with active malignant disease that may be stimulated by growth factors. - Consider renal or hepatic impairment when determining dosing intervals.

Lenograstim may interact with other medications or clinical conditions, influencing its efficacy or safety.

Avoid: - Concurrent use of chemotherapy agents that cause profound myelosuppression without appropriate timing adjustments. - Co‑administration with other hematopoietic growth factors unless clinically justified. - Use with investigational agents that lack safety data in combination with G‑CSF.

Use with caution: - Anticoagulants, as rapid neutrophil recovery can affect bleeding risk. - Corticosteroids, which may mask fever or infection signs. - Immunosuppressive biologics that could alter immune response to G‑CSF.